NAFDAC approves use of Oxford/AstraZeneca COVID-19 vaccine in Nigeria

 

NAFDAC DG, Dr. Mojisola Adeyeye briefs journalists on the use of AstraZeneca Vaccine in Nigeria

Oxford/AstraZeneca COVID-19 vaccine has been approved by the National Agency for Food and Drug Administration and Control (NAFDAC), for utilisation in Nigeria.

The Director-General of NAFDAC, Dr. Mojisola Adeyeye made the announcement during a live briefing on Thursday.

According to her, the vaccine can be stored at 2 to 8-degree centigrade.

The DG further stated that, there are three additional vaccines undergoing evaluation, but the evaluation on Astrazeneca shows that the vaccine is effective against the UK variant of the virus which has been reported in Nigeria.

Dr Adeyeye disclosed that the South African variant has not been reported in Nigeria, adding that the agency has over 30 herbal medicine undergoing review for listing.

The vaccine was recently approved by the W.H.O for emergency use, in a press briefing, NAFDAC says it got the dossier of the vaccine a week ago, and the NAFDAC safety committee went to work immediately to evaluate its safety and efficacy for Nigerians.

The Oxford/AstraZeneca vaccine, also known as ChAdOx1 nCoV-19, or AZD1222, is a viral vector vaccine. Scientists used an adenovirus, originally derived from chimpanzees, and modified it with the aim of training the immune system to mount a strong response against SARS-CoV-2 (the virus that causes COVID-19).

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.